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Abstract
Background: Many patients with advanced cancer depend upon health care providers for symptom assessment.
The extent of agreement between patient and provider symptom assessments and the association of agreement
with demographic- and disease-related factors was examined.
Methods: This cross-sectional study included 1933 patient-health care provider dyads, from 11 European countries.
Patients reported symptoms by using the four-point scales of the European Organization of Research and
Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) version 3, and providers used
corresponding four-point categorical scales. Level of agreement was addressed at the group level (Wilcoxon
Signed-Rank test), by difference scores (provider score minus patient score), at the individual level (Intraclass
Correlation Coefficients, ICCs) and visually by Bland-Altman plots. Absolute numbers and chi-square tests were used
to investigate the relationship between agreement and demographic-, as well as disease-related factors.
Results: The prevalence of symptoms assessed as moderate or severe by patients and providers, respectively, were
for pain (67 vs.47%), fatigue (71 vs. 54%), generalized weakness (65 vs. 47%), anorexia (47 vs. 25%), depression
(31 vs. 17%), constipation (45 vs. 30%), poor sleep (32 vs. 21%), dyspnea (30 vs. 16%), nausea (27 vs. 14%), vomiting
(14 vs. 6%) and diarrhea (14 vs. 6%). Symptom scores were identical or differed by only one response category in
the majority of patient-provider assessment pairs (79-93%). Providers underestimated the symptom in
approximately one of ten patients and overestimated in 1% of patients. Agreement at the individual level was
moderate (ICC 0.38 to 0.59). Patients with low Karnofsky Performance Status, high Mini Mental State-score,
hospitalized, recently diagnosed or undergoing opioid titration were at increased risk of symptom underestimation
by providers (all p < 0.001). Also, the agreement was significantly associated with drug abuse (p = 0.024), provider
profession (p < 0.001), cancer diagnosis (p < 0.001) and country (p < 0.001).
Conclusions: Considerable numbers of health care providers underestimated symptom intensities. Clinicians in
cancer care should be aware of the factors characterizing patients at risk of symptom underestimation.
Background
With the growing incidence of cancer in an aging popu-
lation, an increasing number of advanced cancer
patients are not able to report their symptoms and
many depend upon health care providers for symptom
assessment [1,2]. Accurate evaluation of symptom inten-
sities is critical for optimal care and ultimately for
alleviating symptom burden and improving the quality
of life of cancer patients. An inappropriate interpreta-
tion of symptoms may lead to overdose of medication
(e.g. of an opioid), or conversely may leave the patients
undertreated [3,4]. There are several tools for assess-
ment of symptoms in oncology [5,6]. Nevertheless, clini-
cians have called attention to the lack of consensus
about a brief, reliable, bedside symptom assessment tool
[7]. The absence of such a tool may be an obstacle for
routine assessment, optimal symptom control and ulti-
mately for improvement of quality of life in patients
with cancer [3,5,8-10].
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Patient ratings of symptoms are generally considered
the “gold standard” [11,12]. However, sometimes
patients are unable to report on their symptoms, e.g.
when they suffer from confusion [13] or communication
deficits [11], when the symptom distress is severe [11],
or if physical or cognitive disability make them unable
to complete assessments [4]. These patients are often
excluded from studies and there is no consensus about
how their symptoms should be assessed in order to
guide clinical decisions. For patients unable to report
their symptoms we need to rely on proxy assessments.
The usefulness of such proxy reports is dependent on
their agreement with patients’ report of symptom
intensity.
Studies on agreement between patient reports and
proxy observations have been performed in a wide range
of patient populations [14-16], and in different settings,
including palliative care [3,4,17-29]. Studies conducted
among cancer patients and their health care providers
found a poor and variable agreement between patients
and staff [3,17-19,22,24,25]. Some reports have shown
that providers tend to underestimate the intensity of
physical symptoms, such as pain, and overestimate anxi-
ety, depression and distress [14].
The findings of studies investigating agreement on sin-
gle symptoms and exploring which clinical factors that
cause lack of agreement between self-reports and obser-
ver ratings are inconsistent [18,28-30]. Patients’ age,
gender, tumor site, place of evaluation, Karnofsky per-
formance status, time from admittance into palliative
care and time from diagnosis are among the factors
studied previously [18,28-30]. Most studies included a
limited number of patients, focused on only a few symp-
toms related to quality of life and were performed in a
single department. To use provider reports of patients’
symptoms to guide clinical decisions, we need to know
which symptoms that can be reliably reported by health
care providers and whether certain subgroups of
patients are at risk of symptom over- or underestima-
tion by providers.
Therefore, a large-scale study including patients trea-
ted with opioids for cancer pain from 11 different Eur-
opean countries was conducted. One of the objectives of
the study was to examine the extent of agreement
between patient and health care provider assessments,
including the association with demographic- and
disease-related factors.
Methods
Patients
Patients treated in 17 different palliative care centers,
outpatient clinics, general or cancer wards in 11 coun-
tries were eligible for The European Pharmacogenetic
Opioid Study (EPOS), a multicenter, multinational study
performed between February 2004 and April 2008.
EPOS was designed to study symptoms experienced by
cancer pain patients and the pharmacogenetics of
opioids in these patients. The examination of agreement
on symptom assessments between patients and health
care providers was one of the pre-specified objectives of
the study. All patients considered for inclusion were 18
years of age or older, had a verified diagnosis of malig-
nant disease and had used a regularly scheduled opioid
treatment corresponding to step III at the World Health
Organization’s analgesic ladder for cancer pain for at
least three days. Patients could only participate in the
study once. The exclusion criterion was insufficient
command of the language spoken in the study center.
Patients were informed of the study by their health care
provider and gave written informed consent. The study
was performed according to the rules of the Helsinki-
declaration and approved by each country’s or study
center’s ethical committee.
Symptom assessments
Patients and health care providers (nurses or physicians)
assessed symptoms independently on the same day. The
symptoms assessed were pain, fatigue, generalized weak-
ness, anorexia, depression, constipation, sleep distur-
bance, dyspnea, nausea, vomiting and diarrhea. The
health care providers registered symptom severities dur-
ing the past 24 hours on a four-point verbal rating scale
with the descriptors none, mild, moderate and severe.
Patients reported their symptoms during the past week
by answering the European Organization of Research
and Treatment of Cancer Core Quality of Life Question-
naire (EORTC QLQ-C30) version 3 [31]. Symptoms
were assessed on a four-point verbal rating scale by the
descriptors “not at all”, “a little”, “quite a bit” and “very
much”. All symptoms, except fatigue were assessed by
single items of the EORTC QLQ-C30. Fatigue was
assessed with a scale ranging from zero to 100 including
three items: Did you need to rest?, Have you felt weak?
and Were you tired?. None of these items were identical
with the fatigue item providers responded to. Therefore,
the entire fatigue scale was recoded into a four-point
scale with increasing symptom intensity from 1 to 4:
0-24 was recoded into one, 25-49 was recoded into two,
50-74 was recoded into three and 75-100 was recoded
into four.
Factors associated with agreement
The possible association between patient-provider agree-
ment and several demographic- and disease-related fac-
tors such as age, gender, Karnofsky Performance Status,
tumor site, time since diagnosis and affiliation to depart-
ment is incompletely understood [18,28-30]. The exist-
ing literature suggest that agreement might be
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influenced by such factors (i.e. less agreement as perfor-
mance status worsens [28], in male patients [29], in
younger patients [30], in hospitalized patients [30], in
patients with certain cancer diagnoses [30]) but the find-
ings are inconsistent. Therefore, it was decided to
perform exploratory analyses of demographic-and dis-
ease-related factors thought to be associated with
patient-provider agreement based on existing literature
and clinical experience. The patient characteristics age,
gender, body mass index (BMI), previous or ongoing
abuse of alcohol or drugs (yes or no), cancer diagnosis
and presence of metastasis were registered by a health
care provider. Use of medical treatment including
opioids and chemotherapy was obtained from the
patients’ medical records. The health care providers also
noted the time since diagnosis in months, time since
start of opioid treatment in months, status of present
opioid treatment (as recently initiated and still under
titration or as stable dosing) and whether the patient
was treated as an inpatient or outpatient. Health care
providers assessed cognitive function by performing the
Mini Mental State (MMS) examination, scoring the
patient between zero and 30, where scores of 23 or less
indicated cognitive failure [13,32,33]. In addition, health
care providers assessed functional status by the
Karnofsky Performance Status, scoring the patient
between zero and 100 [34].
Statistics
Collection and organization of the data were performed
by the Pain and Palliation Research Group, Norwegian
University of Science and Technology. The statistical
software SPSS for Windows version 16.0 was used for
all statistical analyses. If data were missing from patients
or health care providers on a single symptom, these
data were eliminated from analyses involving that vari-
able. No imputations were performed.
Some patients did not report their own symptoms.
The definition of not self-reporting was set as answering
less than half (< 15) of the questions of the EORTC
QLQ-C30. Demographics were reported as absolute
numbers, percent, mean and standard deviation (SD).
Mann-Whitney U and Fisher’s exact tests (for 2 ×
2-tables) were used to compare respondents and non-
respondents.
The level of agreement between patient- and health
care provider assessments was examined by four differ-
ent approaches. First, agreement at the group level was
addressed by the Wilcoxon Signed-Rank test comparing
intensity of symptoms as assessed by patients and health
care providers. Second, difference scores for each symp-
tom (difference score = health care provider score
minus patient score) were calculated to examine good
agreement (difference score within ± 1), underestimation
(difference score ≤ -2) and overestimation (difference
score ≥ 2) by health care providers, compared to patient
scores which were considered as the gold standard.
Variants of this approach have been used in several
previous studies [16,19,27-29].
Third, as a measure of agreement on symptom scores
between patients and health care providers at the indivi-
dual level, intraclass correlation coefficients (ICCs) were
computed by a two-way mixed effect model and an abso-
lute agreement definition. ICCs are reported with 95 per-
cent confidence intervals and serve as indicators of
chance-corrected agreement at the individual level [35].
Guidelines used for interpretation of ICCs were based on
studies demonstrating that for ordinal data ICCs are math-
ematically equivalent to the weighted kappa statistic
[36,37] and the ranges used in previous studies of cancer
patient and proxy agreement [17,27,38]: ≤ 0.40 poor to fair
agreement, 0.41-0.60 moderate agreement, 0.61-0.80 good
agreement and 0.81-1.00 excellent agreement. Fourth, data
was examined visually by plotting the differences between
the two measures (difference score = health care provider
score minus patient score) against their individual means
in Bland-Altman plots. These plots are useful for evaluat-
ing whether there is any systematic difference between the
methods or whether the degree of random variation
changes with the mean value [39].
To address whether demographic- and disease-related
factors were associated with the agreement between
patients and providers, analyses on how these influenced
the number and percentage of comparisons where there
was good agreement (difference score within ± 1),
where the health care provider underestimated (differ-
ence score ≤ -2) and overestimated (difference score
≥ 2) were performed [19,27]. Chi-Square tests were used
to investigate whether agreement was significantly asso-
ciated with these previously mentioned variables.
Results
Patients
The EPOS included 2294 patients. Their mean age was
62 (SD 12) years. The mean Karnofsky Performance
score of this patient population was 59 (SD 17), mean-
ing that most patients required some help, but could
take care of most personal requirements [34]. The mean
total Mini Mental State (MMS)-score was 27 (SD 3). On
average it was 32 months (SD 46) since the cancer was
diagnosed and five months (SD 11) since opioid treat-
ment started. Men (52%) and women (48%) were equally
represented in the study. The majority was hospitalized
(81%), Caucasian (97%) patients with one or more
metastases (83%). Cancer diagnoses, site of metastases
and countries are given in Table 1.
Three hundred and fifty-six patients answered less
than 15 questions in the EORTC QLQ-C30 and were
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categorized as non-respondents. In addition observer
rating of symptoms was missing for five patients, mean-
ing that this study yielded 1933 patient and proxy
assessment dyads. In general, patients not giving a self-
report of symptoms were older, had lower Karnofsky
Performance Status, lower scores on MMS, were more
recently diagnosed with cancer, opioid treatment was
more recently initiated and they were more often hospi-
talized as compared to those who completed the assess-
ment form (Table 1). The most common reason for not
Table 1 Demographics of patients
Respondents (N =
1933)
Non respondents (N =
356)
p-valuea
N (%) Mean (SD) N (%) Mean (SD)
Age 61.6 (12.1) 65.7 (12.9) < 0.001
Karnofsky Performance Status (KPS) 61.6 (16.4) 46.0 (16.0) < 0.001
Mini Mental State (MMS), total score 26.9 (3.3) 25.7 (4.0) 0.003
Time since diagnosis (months) 32.8 (46.7) 25.3 (44.3) 0.001
Time on opioids (months) 5.2 (11.3) 3.1 (7.1) 0.002
Gender Female 922 (47.7) 165 (47.1) 0.862
Male 1011 (52.3) 185 (52.9)
Department Hospitalized patients 1513 (78.3) 338 (97.1) < 0.001
Out-patients 420 (21.7) 10 (2.9)
Status of opioid treatment Recently initiated, titration 353 (18.4) 94 (27.5) < 0.001
Stable dosing 1564 (81.6) 248 (72.5)
Metastasesb Bone 875 (45.3) 146 (42.0) 0.266
CNS 104 (5.4) 28 (8.0) 0.060
Liver 466 (24.1) 95 (27.3) 0.223
Lung 426 (22.0) 77 (22.1) 1.000
Other 762 (39.4) 151 (43.4) 0.172
Cancer diagnosisb Breast 268 (13.9) 33 (9.5) 0.025
Female reproductive organs 145 (7.5) 29 (8.3) 0.584
Gastrointestinal 442 (22.9) 83 (23.8) 0.730
Haematological 113 (5.8) 20 (5.7) 1.000
Head and neck 105 (5.4) 20 (5.7) 0.799
Lung 346 (17.9) 71 (20.6) 0.257
Other 168 (8.7) 40 (11.5) 0.106
Prostate 230 (11.9) 34 (9.7) 0.275
Unknown origin 51 (2.6) 11 (3.2) 0.591
Urological 139 (7.2) 27 (7.7) 0.737
Country Denmark 29 (1.5) 2 (0.6) 0.213
Finland 30 (1.6) 0 0.010
Germany 273 (14.1) 178 (50.0) < 0.001
Greece 5 (0.3) 0 1.000
Iceland 145 (7.5) 5 (1.4) < 0.001
Italy 398 (20.6) 62 (17.4) 0.195
Lithuania 54 (2.8) 0 < 0.001
Norway 475 (24.6) 88 (24.7) 0.947
Sweden 119 (6.2) 16 (4.5) 0.270
Switzerland 114 (5.9) 1 (0.3) < 0.001
United Kingdom 291 (15.1) 4 (1.1) < 0.001
Reason for not completing all assessment forms Did not want to complete 96 (27.8)
Too ill 177 (51.3)
Unknown reason 72 (20.9)
aP-values from Mann-Whitney U test or Fisher’s Exact test (2 × 2-tables)
bSome patients had more than one cancer diagnosis and more than one localization of metastases, consequently the sum of percentages is larger than 100.
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completing all assessments was that the patients were
too ill.
Agreement between patients and health care providers
Nurses assessed the symptoms of 994 patients (51%),
physicians assessed the symptoms of 735 patients (38%)
and data about the health care provider profession was
missing for 204 patients (11%). Health care providers
systematically reported the percentages of moderate or
severe symptoms as lower than the patients did. The
percentages of patients with symptoms assessed as mod-
erate or severe by patients and providers respectively,
were for pain 67 and 47, for fatigue 71 and 54, for gen-
eralized weakness 65 and 47, for anorexia 47 and 25, for
depression 31 and 17, for constipation 45 and 30, for
poor sleep 32 and 21, for dyspnea 30 and 16, for nausea
27 and 14, for vomiting 14 and 6 and for diarrhea 14
and 6 (Table 2). Health care providers underestimated
symptom intensity at the group level (p < 0.001 for all
symptoms) (Table 2).
Direct under- and overestimations were calculated on
the basis of difference scores. Again, underestimation of
symptoms by health care providers was far more com-
mon than overestimation (Table 3). For instance anor-
exia was underestimated in 20 percent of assessment-
pairs and overestimated in two percent. In a majority of
patient-provider assessment pairs (79 to 93 percent) the
responses were identical or differed by only one
response category. The highest levels of agreement were
found for pain, vomiting and diarrhea, where 90 percent
of assessment-pairs showed complete agreement or dif-
fered by only one response category. Fatigue, anorexia
and constipation were the symptoms most frequently
underestimated by health care providers.
At the individual level, the patient-provider agreement
was evaluated for each symptom by the ICC (Table 4).
Table 2 Prevalence and intensity of symptoms as rated by patients and health care providers
Symptom assessments Wilcoxon signed-rank testa
Intensity None Mild Moderate Severe Total
Absolute number (%) N (%) N (%) N (%) N (%) N
Pain Patient 124 (6.4) 508 (26.4) 799 (41.5) 492 (25.6) 1923 -18.5 b
Provider 253 (13.1) 761 (39.5) 691 (35.8) 223 (11.6) 1928
Fatiguec Patient 142 (7.4) 423 (21.9) 634 (32.8) 731 (37.9) 1930 -18.3 b
Provider 230 (11.9) 661 (34.3) 741 (38.5) 294 (15.3) 1926
Generalized weakness Patient 153 (8.0) 517 (27.0) 712 (37.1) 536 (27.9) 1918 -16.1 b
Provider 281 (14.6) 740 (38.3) 635 (32.9) 275 (14.2) 1931
Anorexia Patient 510 (26.5) 504 (26.2) 477 (24.8) 432 (22.5) 1923 -20.2 b
Provider 910 (47.4) 535 (27.9) 322 (16.8) 154 (8.0) 1921
Depression Patient 639 (33.4) 683 (35.7) 397 (20.8) 192 (10.0) 1911 -16.8 b
Provider 966 (50.1) 644 (33.4) 263 (13.6) 57 (3.0) 1930
Constipation Patient 583 (30.3) 476 (24.8) 471 (24.5) 392 (20.4) 1911 -17.2 b
Provider 856 (44.4) 487 (25.3) 393 (20.4) 192 (10.0) 1928
Poor sleep Patient 735 (38.2) 572 (29.7) 409 (21.2) 209 (10.9) 1925 -13.8 b
Provider 976 (50.8) 554 (28.8) 309 (16.1) 84 (4.4) 1923
Dyspnea Patient 801 (41.7) 552 (28.7) 362 (18.8) 208 (10.8) 1923 -18.5 b
Provider 1199 (62.1) 414 (21.5) 219 (11.3) 98 (5.1) 1930
Nausea Patient 871 (45.2) 530 (27.5) 342 (17.7) 184 (9.5) 1927 -18.0 b
Provider 1222 (63.3) 439 (22.7) 207 (10.7) 62 (3.2) 1930
Vomiting Patient 1317 (68.3) 351 (18.2) 161 (8.4) 99 (5.1) 1928 -16.2 b
Provider 1635 (84.7) 182 (9.4) 83 (4.3) 30 (1.6) 1930
Diarrhea Patient 1334 (69.6) 313 (16.3) 183 (9.5) 88 (4.6) 1918 -16.5 b
Provider 1664 (86.2) 157 (8.1) 84 (4.4) 26 (1.3) 1931
aWilcoxon signed-rank test calculations are based on rankings of the differences found by subtracting the patient’s symptom score from the provider’s symptom
score. For all symptoms, the sum of the negative difference ranks was larger than the positive difference ranks indicating that health care providers tend to
underestimate symptom intensity compared to patients.
bp < 0.001
c Fatigue was originally assessed in EORTC QLQ-C30 with a scale ranging from 0 to 100. To ensure comparability with the four-point fatigue item assessed by
providers, the fatigue scale was recoded into a four-point scale with increasing symptom intensity from 1 to 4: 0-24 was recoded into 1, 25-49 was recoded into
2, 50-74 was recoded into 3 and 75-100 was recoded into 4.
Laugsand et al. Health and Quality of Life Outcomes 2010, 8:104
http://www.hqlo.com/content/8/1/104
Page 5 of 13
Agreement for anorexia was poor to fair (ICC < 0.4),
whereas the ICC of all other symptoms was of a moder-
ate magnitude (ICC 0.4-0.6). The individual differences
between the two assessments (difference score = health
care provider score minus patient score) were assigned
as the ordinate (y-axis) and the individual means as the
abscissa (x-axis), in Bland-Altman plots (Figure 1 and
Figure 2). The size of the markers reflect the number of
individual observations and only the line of equality (dif-
ference = 0) is shown. The Bland-Altman plot of pain
showed that the best agreement was found at intermedi-
ate levels of symptom intensity (Figure 1a). The Bland-
Altman plots of fatigue and generalized weakness
demonstrated increasing agreement with increasing
symptom intensity (Figure 1b and 2a). For constipation,
anorexia, depression and poor sleep (Figure 1c, 2b, c
and 2d) the Bland-Altman plots showed a fair agree-
ment at all levels of symptom intensities, with the
majority of agreement-pairs within ± 1 difference scores.
For the symptoms that were less frequent, like vomiting,
dyspnea, nausea and diarrhea (Figure 1d, 2e, f and 2g)
most patients and health care providers agreed on
absence of the symptom.
Factors associated with symptom agreement
The 1933 patient-provider dyads assessing 11 symptoms
yielded 21 263 paired symptom observations. The total
number of dyads differed somewhat due to missing data
(Table 5). For all symptom assessment pairs, the agree-
ment between patients and their health care provider
was not associated with the patients’ age, gender, BMI,
previous abuse of alcohol, use of chemotherapy during
the past 24 hours or presence of metastatic disease
(Table 5). Karnofsky Performance Status had a substan-
tial effect on agreement. Large patient-provider discre-
pancies were more prevalent in patients with a very low
(≤ 25) or a moderately impaired (51 to 75) performance
status. Higher MMS-scores (> 23) were associated with
more underestimation of symptom intensity by health
care providers as compared to patients with lower
MMS-scores (≤ 23). Health care providers more often
underestimated symptoms in recently diagnosed patients
and patients that received a recently initiated opioid still
being titrated. Patient-provider agreement was better
among outpatients than hospitalized patients. Overesti-
mation of symptoms by health care providers was more
common in patients with a history of drug abuse (3%)
Table 3 Under- and overestimation of symptoms by health care providers as compared to patients
Symptom (difference) Health care provider underestimation Good agreement Health care provider overestimation
-3 -2 % 0 ± 1 % 2 3 %
Pain 28 148 9.2 904 822 90.0 16 0 0.8
Fatigue 32 226 13.4 795 838 84.9 30 2 1.7
Generalized weakness 26 178 10.6 781 883 86.8 44 4 2.5
Anorexia 127 243 19.4 865 636 78.5 33 8 2.1
Depression 50 149 10.4 1028 652 88.1 28 1 1.5
Constipation 66 156 11.6 1101 570 87.2 21 3 1.3
Poor sleep 46 150 10.2 1037 649 88.0 26 7 1.7
Dyspnea 41 153 10.1 1127 577 88.8 17 5 1.1
Nausea 50 149 10.3 1177 534 88.9 13 1 0.7
Vomiting 39 87 6.5 1445 346 93.0 8 0 0.4
Diarrhea 33 106 7.3 1465 307 92.5 4 1 0.3
Number and percentage of patient-provider pairs with symptom scores showing good agreement (health care provider minus patient score within ± 1),
considerable underestimation (health care provider minus patient score ≤ -2) and considerable overestimation (health care provider minus patient score ≥ 2).
Table 4 Difference scores and intraclass correlation
coefficients for patient-provider-pairs of symptom
severity scores
Total Difference
scorea
Intraclass
correlation
Symptom N Mean SD ICCb 95% CI
Pain 1918 -0.40 0.86 0.46 0.31 - 0.57
Fatigue 1923 -0.44 0.97 0.40 0.27 - 0.51
Generalized weakness 1916 -0.38 0.96 0.41 0.31 - 0.50
Anorexia 1912 -0.58 1.10 0.38 0.22 - 0.51
Depression 1908 -0.38 0.90 0.46 0.33 - 0.55
Constipation 1917 -0.39 0.92 0.59 0.47 - 0.68
Poor sleep 1915 -0.31 0.93 0.49 0.41 - 0.56
Dyspnea 1920 -0.39 0.85 0.56 0.41 - 0.66
Nausea 1924 -0.38 0.84 0.53 0.39 - 0.63
Vomiting 1925 -0.28 0.70 0.51 0.40 - 0.60
Diarrhea 1916 -0.28 0.69 0.51 0.39 - 0.60
aDifference scores were calculated by subtracting the patient’s symptom score
from the health care provider’s symptom score.
bIntraclass correlation coefficient, two way mixed effect model; absolute
agreement definition; single measure ICC.
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than in patients with no such history (1%). Both under-
and overestimation was more common when the symp-
toms were assessed by physicians (11% and 3% respec-
tively), as compared to assessment by nurses (10% and
2% respectively). The frequency of underestimation var-
ied between cancer diagnoses and countries (Table 5).
Discussion
In this large, European cross-sectional study a moderate
agreement on symptom assessment between cancer
patients and their health care providers was observed
(ICC range 0.38 to 0.59). Health care providers underes-
timated symptom intensity in approximately 10% of
patients, with some variations between cancer diagnoses
and substantial variations between countries. Patients
with low Karnofsky Performance Status, MMS-scores of
24 or higher, who were hospitalized, recently diagnosed
or still undergoing opioid titration, were at increased
risk of symptom underestimation by health care
providers.
Our examinations of the agreement between patient
and provider assessments showed that health care provi-
ders tended to underestimate all symptoms and that
underestimation was present in 6.5 to 19.4% of the
patient-provider assessment pairs. The highest rates of
underestimation were found for anorexia (19.4%) and
fatigue (13.4%), which were among the most “subjective”
symptoms investigated. As similar proportions of
Figure 1 Bland-Altman plots, one for each symptom (see also Figure 2). The difference between patient and provider score (difference
score = health care provider score minus patient score) plotted against mean symptom score. The size of markers reflect the number of
individual observations and only the line of equality (difference = 0) is shown. Negative differences mean that providers underestimated the
symptom. The larger the size of the markers at one side of the line of equality, the larger was the tendency of a systematic difference between
assessments (i.e. more observations below the line suggest that providers had a negative bias and underestimated symptom intensity). Whether
differences between provider and patient assessments changes with the mean value of symptom intensity is determined by looking for patterns
along the x-axis. (A): Pain. (B): Fatigue. (C): Constipation. (D): Vomiting.
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Figure 2 Bland-Altman plots, one for each symptom (see also Figure 1). The difference between patient and provider score (difference
score = health care provider score minus patient score) plotted against mean symptom score. The size of markers reflect the number of
individual observations and only the line of equality (difference = 0) is shown. Negative differences mean that providers underestimated the
symptom. The larger the size of the markers at one side of the line of equality, the larger was the tendency of a systematic difference between
assessments (i.e. more observations below the line suggest that providers had a negative bias and underestimated symptom intensity). Whether
differences between provider and patient assessments changes with the mean value of symptom intensity is determined by looking for patterns
along the x-axis. (A): Generalized weakness. (B): Anorexia. (C): Depression. (D): Poor sleep. (E): Dyspnea. (F): Nausea. (G): Diarrhea.
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Table 5 Factors associated with agreement across all pairs of symptom observations (N = 21263)a
Factors possibly affecting agreement Health care
provider
underestimation
Good
agreement
Health care
provider
overestimation
Chi-square
Number % Number % Number %
Age ≤ 60 1013 10.9 8122 87.7 126 1.4 0.629
> 60 1268 10.7 10410 88.0 146 1.2
Body Mass Index < 25 1378 10.3 11855 88.5 169 1.3 0.583
≥ 25 693 9.8 6274 88.9 89 1.3
KPSb < 80 1808 11.1 14110 86.8 347 2.1 0.032
≥ 80 474 9.9 4240 88.2 94 2.0
Mini Mental State,
total score
≤ 23 265 9.5 2455 87.6 81 2.9 < 0.001
> 23 1927 11.3 14806 86.7 340 2.0
Time since
diagnosis (months)
≤ 3 550 12.5 3797 86.5 43 1.0 < 0.001
> 3 1420 9.6 13162 89.0 204 1.4
Gender Female 1122 11.1 8812 87.5 136 1.4 0.261
Male 1161 10.5 9727 88.2 136 1.2
Department Hospitalized patients 1992 12.1 14314 86.7 201 1.2 < 0.001
Out-patients 291 6.3 4225 92.1 71 1.5
Status of
opioid treatment
Recently initiated 593 15.4 3219 83.5 43 1.1 < 0.001
Stable dosing 1679 9.8 15159 88.6 228 1.3
Previous or ongoing
abuse alcohol
Yes 113 9.8 1017 88.5 19 1.7 0.304
No 2161 10.9 17477 87.9 252 1.3
Previous or ongoing
abuse drugs
Yes 19 9.2 180 87.4 7 3.4 0.024
No 2250 10.8 18283 87.9 267 1.3
Chemotherapy the
past 24 hours
Yes 331 10.4 2833 88.6 32 1.0 0.180
No 1952 10.9 15706 87.8 240 1.3
Profession of health
care providerc
Physician 859 10.6 6970 86.2 261 3.2 < 0.001
Nurse 1090 10.0 9573 88.1 208 1.9
Metastases None 406 11.2 3176 87.7 39 1.1 0.430
One or more 1917 11.0 15352 87.7 233 1.3
Cancer diagnosis Breast 292 10.0 2609 89.0 31 1.1 < 0.001
Female reproductive organs 183 11.5 1383 87.2 20 1.3
Gastrointestinal 455 9.4 4306 89.4 58 1.2
Haematological 142 11.5 1077 87.3 14 1.1
Head and neck 148 12.8 983 85.3 21 1.8
Lung 481 12.8 3241 86.0 46 1.2
Other 198 10.8 1607 87.6 29 1.6
Prostate 237 9.4 2233 89.0 40 1.6
Unknown origin 53 9.6 491 89.3 6 1.1
Urological 171 11.4 1317 87.5 18 1.2
Country Denmark 3 0.9 304 95.3 11 3.5 < 0.001
Finland 25 7.7 295 90.8 5 1.5
Germany 662 22.4 2231 75.5 61 2.1
Greece 5 9.3 48 88.9 1 1.9
Iceland 105 6.6 1437 90.3 49 3.1
Italy 137 3.1 4196 96.1 34 0.8
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underestimation have been demonstrated previously
[15,18,28,29], influence from subjective terminology and
recoding of the fatigue scale was considered as less likely
and the findings may rather reflect the known trend
towards better agreement when the information assessed
is observable and concrete [14]. This was also illustrated
by the low level of underestimation (6.5%) for vomiting.
Agreement at the individual level was only moderate as
measured by ICCs ranging between 0.38 and 0.59. The
ICC, which is a suitable statistical measure of agreement
correcting for the chance-expected agreement, and the
presentation of agreement as absolute numbers and per-
centages in Table 3 are complementary approaches as
they differ both in perspective and operationalization
[27].
The present findings of provider underestimation and
moderate ICCs were in contrast to findings in primary
care where general practitioners and nurses overesti-
mated symptoms and ICCs were higher [19]. Also, in a
review of health care providers’ role for evaluation of
patients with chronic diseases including cancer, Sneeuw
et al. reported that providers tended to rate patients as
having more symptomatology than the patients did
themselves [15]. However, the quality of the studies
comparing patient and provider assessments was
assessed as rather poor [15]. Other studies have reported
that health care providers tend to underestimate physi-
cal symptoms [4,20,23,24,28], whereas anxiety, depres-
sion and distress of symptoms are overestimated [14]. In
the present study there was no directional difference
between agreement on physical and psychological symp-
toms. However, the Bland-Altman plots of agreement by
level of symptom intensity showed differences between
symptoms. For fatigue and generalized weakness, the
agreement increased at higher symptom intensities,
whereas the agreement on less prevalent symptoms was
best at low symptom intensities. The latter finding was
in line with observations in primary care where symp-
tom agreement was best for absent symptoms [19]. This
argues for that the differences in agreements between
studies are likely to be influenced by the number of
patients with moderate or severe symptoms included in
the study.
Symptom underestimation by health care providers
was associated with low Karnofsky Performance Status,
high MMS-score, hospitalization, recently diagnosed
cancer and ongoing opioid titration. Of the previous stu-
dies examining possible factors associated with patient-
provider agreement one study found no associations
[18], and three studies found better agreement in sub-
groups of patients characterized by certain demo-
graphic- and disease-related factors [28-30]. However,
the findings were not conclusive because the analyses
were dispersive, the findings were difficult to explain
clinically and there was a lack of consistency. The signif-
icant relationship between Karnofsky Performance Sta-
tus and agreement found in the present study was in
line with the existing literature, but there was no linear
[28,29] or U-shaped [11,27] correlations as described
previously. To our knowledge, an association with
MMS-score has not been documented before. The asso-
ciation might reflect that patients with low MMS-scores
are identified as generally more influenced by disease
and therefore the observer ratings agreed more closely
with the patient ratings. The status of patients hospita-
lized, recently diagnosed or undergoing opioid titration
can at a group level be considered as fluctuating. There-
fore, the finding of more discrepancies between patient
and provider assessments in these patients was not sur-
prising. This finding is also in line with a previous study
showing less agreement in hospitalized patients [30].
Based upon these results the presence of such factors
could alert clinicians to recognize that health care provi-
ders may underestimate symptoms in these patients.
The factors associated with agreement were broadly
similar to those characterizing the patients not able to
complete the EORTC questionnaire, possibly indicating
that patients unable to give self-reports are at risk of
underestimation of symptoms by health care providers.
Drug abuse and cancer diagnosis were also signifi-
cantly related to agreement, but the magnitude of differ-
ences was considered as not clinically important. As
seen in previous studies, the nurse assessments agreed
more closely with patient ratings than physician assess-
ments [4,19]. The substantial variations in agreement
observed between countries might be of relevance,
Table 5 Factors associated with agreement across all pairs of symptom observations (N = 21263)a (Continued)
Lithuania 44 7.5 533 90.5 12 2.0
Norway 546 10.5 4578 88.4 54 1.0
Sweden 182 14.0 1107 85.3 9 0.7
Switzerland 281 22.8 937 76.1 13 1.1
United Kingdom 293 9.2 2874 89.8 33 1.0
aNumber of paired symptom observations. Across one pair of raters and 11 questions for 1933 patients (1 × 11 × 1933 = 21263) (varies due to missing data).
bKarnofsky performance status
cFor 204 patients, the profession of the health care provider was not reported.
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reflecting that factors influencing either patient- or pro-
vider reports may vary between countries. However, the
study design does not allow us to reach a firm conclu-
sion if this variation is truly related to country or if it
also related to each specific center.
For the analyses of agreement, the patient ratings were
used as a “gold standard to which the health care provi-
der assessments were compared. In reviews, the patients’
role as a gold standard for assessment has been ques-
tioned [15,40]. A study comparing responses from
patients, physicians, nurses and significant others found
that deviant scores of more than one response category
were most often caused by the patients, indicating either
that the quality of all proxy-derived information was
poor or that patients’ responses are of questionable
validity [27]. Patient reports may not reflect the true
experience of symptoms for various reasons, such as
psychological denial, barriers towards reporting symp-
toms, a wish to please the nurse/doctor or an impres-
sion that emphasizing symptoms is needed to secure
help from health care providers. Therefore, to use a
combination of patient reports (when available), the
caregiver’s perceptions and objective signs could be of
benefit both in clinical decisions and future research
[4,7].
The findings of this study might have direct clinical
implications for the care of cancer patients. Underesti-
mation of symptoms by health care providers in cancer
care might cause undertreatment of symptoms and less
favorable outcome. Insight into the limitations of obser-
ver rating may improve the health care providers’ ability
to identify symptoms that need treatment. To increase
rates of agreement, systematic screening tools used reg-
ularly or programs for further training of communica-
tion skills could be introduced [41]. Future research
could address the consequences of symptom underesti-
mation in cancer care and the importance of interven-
tions to reduce disagreement between patients and
providers. When health care provider assessments
replace patient rating in those not able to report their
symptoms, the identification of risk factors for erro-
neous assessments by health care providers is important
[24]. Our findings of factors influencing agreement may
be elaborated in future studies investigating whether
agreement can be improved by adjusting for systematic
deviations between patient and health care provider
assessments in such situations.
This is to our knowledge the largest study comparing
the assessment of individual symptoms between patients
and health care providers in cancer care across several
countries. As in other studies among advanced cancer
patients, self-assessment was not possible to obtain for a
considerable number of patients (N = 365). The patients
not able to report symptoms had similar characteristics
as those who had their symptoms underestimated by
providers. Therefore, the true number of patients being
underestimated is not likely to be falsely overestimated
due to missing values. Patients rated their symptoms in
the extensively validated EORTC QLQ-C30, whereas
health care providers rated the same symptoms using a
clinically applicable four-point verbal rating scale.
Patients reported their symptoms during the past week,
whereas health care providers assessed symptoms during
the past 24 hours, a difference in time frame that might
introduce differences in both prevalence and intensity of
reported symptoms. Thus, it could be argued that
patient- and provider-instruments differed. However, to
compare the actual assessments currently performed in
clinical research it was decided to apply the instrument
used in most studies on self-reported symptoms in can-
cer care (EORTC QLQ-C30) and the bedside observer
assessment tool used in recent European Association for
Palliative Care (EAPC) endorsed studies [42]. The pre-
sent study compared assessments by patients and provi-
ders and was not designed to compare assessments
performed by subgroups of health care providers (nurses
versus physicians). Future studies needs to be designed
specifically to investigate differences between nurses and
physicians in terms of ability to assess patient symptoms
as the findings of previous studies are inconsistent
[4,19,29]. Furthermore, studies in samples of other
racial/ethnic composition and studies including patients
at different levels of the disease-trajectory are needed to
determine the generalizability of the findings of the pre-
sent study.
We recognize that this study have some limitations. In
the analyses to identify risk factors of disagreement
between patients and providers, pairs of assessments for
all symptoms were pooled, to avoid multiple testing.
This strategy did not allow us to address whether the
factors associated differently with each symptom.
Furthermore, data from each center on numbers and
characteristics of patients not approached or declining
to take part in the study was not obtained. However, the
characteristics of patients included were found to be
representative for cancer patients. The pooling of data
across countries may be seen as a limitation as there
were substantial variations in agreement between coun-
tries, but it may also be a strength as it increase the
sample size and protects against the tendency towards
report of lower overall levels of patient-proxy agreement
shown in smaller studies [15]. The selection of centers
in each country was based upon researchers volunteer-
ing to participate in this European multi-center study.
These centers are not necessarily representative for each
country’s general health care system. In order to accu-
rately describe the influence of country, we believe a
study should include several randomly selected centers
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from each country in the analysis. Obviously, this was
not done in our study and therefore, we believe that the
data about country effect (Table 5) should be inter-
preted with caution and hence not included in more
comprehensive analyses.
Conclusions
In this large European study, health care providers
assessing cancer patients’ symptoms tended to underes-
timate symptom intensity at the group level and the
agreement with patient ratings at the individual level
was moderate. The differences between patient and pro-
vider assessments can be caused by providers not being
able to exactly interpret the patients’ symptoms or that
different instruments are used for patients and health
care providers. Agreement on rating of symptoms was
associated with demographic- and disease-related fac-
tors. Clinicians involved in care for patients with cancer
should be aware of the potential factors associated with
a risk of symptom underestimation.
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